EGF antibody (AA 956-985)

Catalog No. ABIN5532555

The Rabbit Polyclonal anti-EGF antibody is suitable to detect EGF in samples from Human. It has been validated for WB.

Quick Overview for EGF antibody (AA 956-985) (ABIN5532555)

Target: EGF (Epidermal Growth Factor (EGF))

Reactivity: Human

Host: Rabbit

Clonality: Polyclonal

Conjugate: This EGF antibody is un-conjugated

Application: Western Blotting (WB)

Product Details anti-EGF Antibody

Binding Specificity: AA 956-985

Purification: This antibody is purified through a protein A column, followed by peptide affinity purification.

Immunogen: This EGFR antibody is generated from rabbits immunized with a KLH conjugated synthetic peptide between 956-985 amino acids from human EGFR.

Isotype: Ig Fraction

Application Details

Application Notes: For WB starting dilution is: 1:1000

Restrictions: For Research Use only

Handling

Format: Liquid

Concentration: 0.5 mg/mL

Buffer: Supplied in PBS with 0.09 % (W/V) sodium azide.

Preservative: Sodium azide

Precaution of Use: This product contains Sodium azide: a POISONOUS AND HAZARDOUS SUBSTANCE which should be handled by trained staff only.

Storage: 4 °C,-20 °C

Storage Comment: Store at 4°C for three months and -20°C, stable for up to one year. As with all antibodies care should be taken to avoid repeated freeze thaw cycles. Antibodies should not be exposed to prolonged high temperatures.

Target Details for EGF

Target: EGF (Epidermal Growth Factor (EGF))

Alternative Name: EGF

Background: EGFR is a transmembrane glycoprotein that is a member of a family of protein tyrosine kinases crucial in maintaining a normal balance in cell growth and development. A prototype member of the type 1 receptor tyrosine kinases, EGFR is encoded by the cellular oncogene cerbB1. EGFR has an extracellular ligand binding domain, a single transmembrane region, and cytoplasmic domain which is composed of a tyrosine kinase domain and a carboxy terminal domain. The carboxy terminal domain contains at least four tyrosine autophosphorylation sites. Increased production or activation of EGFR has been associated with poor prognosis in a variety of tumors. EGFR overexpression is observed in tumors of the head and neck, brain, bladder, stomach, breast, lung, endometrium, cervix, vulva, ovary, esophagus, stomach and in squamous cell carcinoma.

Molecular Weight: 134 kDa

Gene ID: 1956

UniProt: P00533

Pathways: NF-kappaB Signaling, RTK Signaling, Fc-epsilon Receptor Signaling Pathway, EGFR Signaling Pathway, Neurotrophin Signaling Pathway, Regulation of Carbohydrate Metabolic Process, Hepatitis C, Protein targeting to Nucleus, Interaction of EGFR with phospholipase C-gamma, Thromboxane A2 Receptor Signaling, EGFR Downregulation